Werewolf Therapeutics reports Q4 2024 net loss of $20.4M; cash runway through Q2 2026

Werewolf Therapeutics, Inc.

Cash and cash equivalents $111.0M at Dec 31, 2024; sufficient to fund operations through Q2 2026.
Net loss $20.4M in Q4 2024 vs $12.0M in Q4 2023; full year net loss $70.5M vs $37.4M.
Collaboration revenue $0 in Q4 2024 as Jazz obligation completed; full year $1.9M vs $19.9M.
WTX-124 monotherapy melanoma expansion arm expected fully enrolled H1 2025; combination arm by end of 2025.
Plan to meet with FDA in H2 2025 for registrational pathways; interim data expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.